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Abstract
Background: Inflammatory bowel diseases (IBD), including mainly ulcerative colitis (UC) and Crohn’s disease (CD), are
inflammatory disorders of the gastrointestinal tract caused by an interplay of genetic and environmental factors. Murine
colitis model induced by Dextran Sulfate Sodium (DSS) is an animal model of IBD that is commonly used to address the
pathogenesis of IBD as well as to test efficacy of therapies. In this study we systematically analyzed clinical parameters,
histological changes, intestinal barrier properties and cytokine profile during the colitic and recovery phase.
Methods: C57BL/6 mice were administered with 3.5% of DSS in drinking water for various times. Clinical and histological
features were determined using standard criteria. Myeloperoxidase (MPO) activity, transepithelial permeability and
proinflammatory mediators were determined in whole colon or proximal and distal parts of colon.
Results: As expected after administration of DSS, mice manifest loss of body weight, shortening of colon length and bloody
feces. Histological manifestations included shortening and loss of crypts, infiltration of lymphocytes and neutrophil,
symptoms attenuated after DSS withdrawal. The MPO value, as inflammation indicator, also increases significantly at all
periods of DSS treatment, and even after DSS withdrawal, it still held at very high levels. Trans-mucosal permeability
increased during DSS treatment, but recovered to almost control level after DSS withdrawal. The production of
proinflammatory mediators by colonic mucosa were enhanced during DSS treatment, and then recovered to pre-treated
level after DSS withdrawal. Finally, enhanced expression of proinflammatory mediators also revealed a different profile
feature in proximal and distal parts of the colon.
Conclusion: Experimental colitis induced by DSS is a good animal model to study the mechanisms underlying the
pathogenesis and intervention against IBD, especially UC.
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Introduction
Inflammatory bowel diseases (IBD), including mainly ulcerative
colitis (UC) and Crohn’s disease (CD), are inflammatory disorders
of the gastrointestinal tract caused by multiple factors, including
genetic and environmental factors, and are characterized by
diarrhea, bloody stools, abdominal pain, and weight loss.
Histological characteristics of IBD include crypt abscesses, crypt
distortion and loss, ulcerationan infiltration of large numbers of
neutrophils, monocytes, and lymphocytes. In past decades, dozens
of different models of experimental IBD have been developed to
investigate pathogenesis and improve treatment options. Although
no model serves as a complete surrogate for IBD, many enable us
to study the pathogenic characteristics of IBD, to identify novel
genes that are possibly involved in disease susceptibility, and to
characterize pivotal immunological molecules and processes. IBD
experimental models can generally fall into five different
categories: I) Gene knockout (KO) models: Interleukine (IL)-2/
IL-2 receptor-alpha [1], IL-10 [2], T cell receptor (TCR) [3],
trefoil factor [4], Tumor necrosis factor (TNF)-39 untranslated
region (UTR) [5]; II) Transgenic models: IL-17 [6], signal
transducer and activating transcription (STAT)-4 [7], HLA B27
[8]; III) spontaneous colitis models: C3H/HejBir [9], SAMP1/
YitFc mice [10]; IV) Inducible colitis models: Trinitrobenzene
sulfonic acid (TNBS) colitis [11,12], dextran sulfate sodium (DSS)
colitis [13], peptidoglycan-polysaccharide (PG-PS) colitis [14] and
V) Adoptive transfer models: heat shock protein (HSP) 60-specific
CD8 T cells transfer induced colitis [15], CD45RB transfer model
[16]. Most commonly, experimental colitis is induced by heparin-
like polysaccharide DSS because of its simplicity and the high
degree of uniformity and reproducibility of the colonic lesions
[16]. By interfering with intestinal barrier function firstly and then
stimulating local inflammation as the secondary phenomenon,
DSS is often used to induce the mouse model of colitis which can
mimic clinical and histoogical features of IBD with UC
characteristics. Although the clinical and histological parameters
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other parameters are unknown. The present work is a rigorous
analysis of the general profile of experimental colitis induced by
DSS, including the clinical, histological characteristics, as well as
inflammatory indicators and mediators in a spatial and temporal
fashion.
Results
Weight loss and colon length shortening during DSS
treatment
We induced experimental colitis in C57BL/6 mice by adding
3.5% DSS to the drinking water for indicated days. DSS intake did
not differ between the different groups of mice (data not shown).
Mice showed different extent of diarrhea, more and grosser rectal
bleeding as DSS treatment progressed, which suggested presence
and development of inflammation. Specially, after 3-days of DSS
treatment, more than 70% (17/24) of mice in 3-, 5-, 9- and 14-day
treated groups had diarrhea and occult blood or gross blood in the
feces, and these signs disappeared in part after DSS was
withdrawn for 4 days (day 9) and complete after DSS withdrawal
for 9 days (day 14). It has been pointed out that 2 (out of 6) mice in
the 5-day DSS treatment group died after DSS withdrawal.
During the period of DSS treatment, the weight loss was noticed
after DSS administration under the indicated days. As shown in
Fig. 1, 3-, and 5-day groups, body weight significantly decreased
during the DSS-treatment, much lower than those in normal
drinking water-treated mice. After DSS withdrawal, mouse body
Figure 1. Mouse body weight changes during DSS treatment. C57BL/6 mice were administered to 3.5% DSS by drinking water for indicated
days. Body weight changes are depicted as means6SEM body weight changes in each group. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0006073.g001
Figure 2. Mouse colon size changes during DSS treatment. C57BL/6 mice were exposed to 3.5% DSS in their drinking water for indicated days.
Colon length removed from euthanized mice is depicted as means6SEM length of the colon in each group. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0006073.g002
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determine the severity of colitis. We found that DSS could lead to
significant reduction of colon length during the treatment as
described in Fig. 2. This colon length shortening became most
severe in 5-day DSS-treated mice compared to drinking water
mice colon (Fig. 2) with a reduction in colon length of around
30%. The reduction could be recovered after withdrawal of DSS,
such as day 9 and day 14 groups. In general, the mice receiving
DSS had a clinical disease activity score of 9.461.1 in 5-day group
based on the score system established previously [17].
Histological characterization
Control mouse colon sections (Fig. 3, 0 day) showed the intact
epithelium, well defined crypt length, and no edema neutrophil
infiltration in mucosa and submucosa, and no ulcers or erosions.
In contrast, colon tissue from DSS treated mice showed
increasingly severe inflammatory lesions extensively throughout
the mucosa during the DSS treatment (Fig. 3 1-, 3-, 5-day), then
attenuating inflammatory lesions throughout the mucosa after
DSS withdrawal. Ulcers, shortening and loss of crypts were seen
focally at the beginning progressing to more extensive areas of
Figure 3. Hematoxylin-stained colon sections of mice treated with DSS at 0, 1, 3, 5, 9 (withdraw after 5 days treatment, 4 days to
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day), which are in agreement with the data described previously
[17,18], then the mucosa were recovered to almost intact after
DSS withdrawal (Fig. 3 9-, 14-day). Submucosal edema increased
during DSS treatment 1-, 3-, 5-day group (Fig. 3) and recovered to
normal state at day 9 and day 14 (Fig. 3); Infiltration of immune
cells including neutrophils and lymphocytes were seen in the
lamina propria in DSS treated mice (Fig. 3 1-, 3-, 5-day), and
cleared after the DSS withdrawal in 9- and 14-day group.
MPO activity
We measured colonic myeloperoxidase (MPO) activity as an
indicator of the extent of neutrophil infiltration into the mucosa.
MPO values were significantly higher in DSS-treated groups than
corresponding controls at all the periods studied. Fig. 4 shows the
quantification in concentrations of this parameter in the
experimental animals. We found that DSS-induced increases of
MPO activity reached to the maximum level of 92628 mUnits/
ug protein at day-5 group, 6-fold higher than that of the controls
(1463.5 mUnits/ug). After DSS was replaced with drinking water,
MPO levels remained significantly higher at 9-day group (6-times
increase as that in 5-day group). In the 14-day group, the MPO
level had declined significantly but still higher than water-drinking
group (Fig. 4).
DSS treated mice exhibit epithelial barrier dysfunction
Epithelial cell barrier function loss is thought to be the initial
inciting event that underlies injury and inflammation in many
intestinal disorders, including IBD [19,20]. Such barrier defects
result in the migration of luminal antigens into the submucosa,
exposing lamina propria immune cells to these antigens, eliciting
inflammatory response and epithelial injury that characterize these
diseases [19,20]. We studied barrier function in water-drinking
mice and DSS treated mice using a FITC-labeled dextran method,
as described in Materials and Methods. Mice were administered
FITC-dextran by gavage, and fluorescence was quantified in the
serum at 4 h after the administration of FITC-dextran. As shown
in Fig. 5, water-drinking mice showed an FITC-dextran of
0.428360.1678 mg of FITC/mg protein. In comparison, there
was ,3-fold increase in FITC-dextran levels in DSS mice in day-5
group (1.7260.4 mg of FITC/mg protein) compared to control
mice, suggesting decreased barrier function in these mice, which is
consistent with data reported previously [21,22].
DSS induces the production of inflammatory mediators
We next considered potential mechanisms which might underlie
the colitis exhibited by DSS treatment. Pro-inflammatory
mediators play central roles in the pathogenesis of IBD including
ulcerative colitis and Crohn’s diseases. Enhanced intestinal
permeability and consequent immune cell infiltration is thought
to increase mucosal production of pro-inflammatory cytokine,
both from epithelial cells as well as immune cells. We employed
real time PCR to study the proinflammatory cytokines thought to
play a pathogeneic role in IBD under DSS treatment in C57BL/6
Figure 4. Determination of MPO enzymatic activity as an index of neutrophils infiltration into the injured tissue. (A): Distal colon; (B):
Proximal colon. Results are expressed as MPO mUnits per mg protein and represent mean6SEM of 3 determinations. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0006073.g004
Figure 5. In vivo permeability assay in colon epithelium of mice
treated with DSS. Results are presented as FITC-dextran in mg/mg
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production of proinflammatory cytokines TNF-a, IL-1b, IL-6,
IL-10, IL-12, IFN-c and KC, as well as chemokine MIP-2.
Furthermore, this stimulation happened very early after the
treatment, in the cases of TNF-a, IL-1b, IFN-c, IL-10 and IL-12,
production increased significantly as early as the first day of
treatment. The production of these proinflammatory cytokines or
chemokines increased progressively during DSS treatment,
reaching a maximum on the 5
th day. After DSS withdrawal, these
mediators remained at high levels until being sacrificed at day 14,
which indicated that the duration of inflammation incited by DSS
lasts a very long time, which implied the potential to turn into
chronic inflammation.
DSS induces increases the productions of inflammatory
mediators in both proximal and distal parts of colon
In order to understand the cytokine expression in histologically
affected distal colon compared to relatively uninvolved proximal
colon, we performed real time PCR of pro-inflammatory cytokines
for samples from proximal and distal colon. As shown in Fig. 7,
with the DSS treatment, the expression of proinflammatory
cytokines IL-1b, TNF-a, IFN-c, IL-6, IL-10, IL-12 and chemokine
KC and MIP-2 increase significantly in comparison in samples
from control mice both in the proximal and distal colon. Although
the absolute increases of these cytokines mRNA were higher in the
distal colon than those for the samples from proximal colon,
especially IL-1b and IL-6 production made ,30-fold increase, as
reported previously [23]; MIP-2 and IFN-c increase around 20
times of their control levels; IL-10 and IL-12 expression were
enhanced up to 4 times, the proximal colon demonstrated
significant increases in these cytokines. IL-6 mRNA increases
more than 10 times, IL-1b and IFN-c increase 5 times of control
levels; however, IL-10 and MIP-2 only demonstrated two-fold
increases of their production, but no increase IL-12 transcript was
detected. TNF-a showed dramatic fold increase in the proximal
colon compared to distal colon although the absolute level of this
cytokine was higher in the distal colon (Fig. 7).
Discussion
This work is the second comparitive study carried out since the
first paper in 1993 from Cooper et al [17]. In addition to the
clinical and histological parameters of colitis described in the
original study, our study includes detailed analysis of cytokine
profile in a spatial and temporal fashion during the colitic and
Figure 6. DSS can increase the production significantly of proinflammatory mediators TNF-a, IL-1b, IL-6, IL-10, IL-12, IFN-c and
chemokines KC and MIP-2. This stimulation happened very early with the treatment, TNF-a, IL-1b, IL-10, IL-12, and IFN-c production increased as
early as the first day. The production of these cytokines reached to the peak at the day 5 of DSS treatment, then decreased after the DSS withdrawal,
but all of them are still high significantly than those in control mice. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0006073.g006
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histological changes were determined based on the phenotypic and
pathologic changes [17,24,25], such as diarrhea, rectal bleeding,
body weight loss and colon shortening, which were the common
phenomenon seen in DSS-induced experimental colitis. Diarrhea
is due to the increased permeability of intestinal cells or
hyperosmolarity in lumen led by DSS [26,27,28]. Weight loss
and the shortening of the colon, as indicators for the severity of
intestinal inflammation, correlate with the pathologic and
histological changes and are consistent markers for colitis
[13,24,25]. As a biochemical indicator for intestinal inflammation,
the assessment of MPO activity is to quantify intestinal
inflammation to assess the tissue damage and extent of infiltration
by inflammatory cells [29].
In addition, there is enhanced inflammatory mediators
production in DSS treated mouse colon during the colitic phase.
Proinflammatory cytokines are local inflammatory mediators,
produced by macrophages, lymphocytes as well as by epithelial
and mesenchymal cells, involved in the development and
pathogenesis of inflammation and immunity [30,31]. We found
that proximal and distal colons express proinflammatory media-
tors at different levels. In control mice, the basal levels of almost all
the cytokines tested are much lower in the proximal colon than
those in distal colon. In general, after DSS treatment, the distal
colon produced much higher levels of proinflammatory mediators
in terms of both folds and absolute value, which suggested that the
distal colon is more affected by DSS, which is consistent with data
published recently [32]. This is in keeping with the severe
histological damage in the distal colon compared to the proximal
colon. An exception was the relative increasing folds of TNF-a,
which was higher in the proximal colon compared to the distal
colon. As expected, the levels of these cytokines return to baseline
during the recovery phase. The mechanisms by which DSS
induces stronger mucosal inflammation in the distal colon than in
proximal colon are not fully understood, but most in vivo and in vitro
studies suggest that DSS causes colitis by interfering directly with
intestinal epithelial cell barrier function including crypt damage
[17,33], which is the primary event that leads to secondary
mucosal inflammatory responses characterized by both Th1 and
Th2 cytokine profiles. These proinflammatory cytokines not only
play a role in the pathogenesis of DSS induced colitis [34], but are
important as intervention targets against colitis.
In conclusion, we present a rigorous analysis of DSS-induced
colitis, a commonly used animal model of IBD, correlating
cytokine profile with clinical and histological parameters as well as
barrier properties. Together, our data provide novel insight
regarding differential expression of cytokines, particularly TNF-a
and IL-6, in the proximal and distal colon rendering this model as
a useful tool to dissect the role of these cytokines in the induction of
inflammation and recovery from it.
Materials and Methods
Mouse colitis model
All experiments were carried out in C57BL/6 mice (8 wk, 18–
22 g) obtained from Jackson Laboratories (Bar Harbor, ME). Mice
were group housed under a controlled temperature (25uC) and
photoperiod (12:12-h light-dark cycle) and allowed unrestricted
access to standard mouse chow and tap water. They were allowed
Figure 7. 5 days of DSS treatment stimulates the production of proinflammatory cytokines differently in proximal and distal parts
of colon. After DSS treatment, the production of cytokines TNF-a, IL-1b, IL-6, IL-10, IL-12, IFN-c and chemokines KC and MIP-2 increases both in
proximal and distal parts of colon. But the increasing folds of TNF-a is higher in proximal colon than that in distal colon, the increasing folds of IL-1b,
IL-10 and KC are almost same in both proximal and distal colon. There are higher folds increases in distal colon than in proximal colon for IL-6, IL-12,
IFN-c and chemokine MIP-2. But the normalized cycles thresholds (NCT) are always lower in distal colon than in proximal colon which means higher
absolute production of these mediators in distal part than in proximal parts of the colon. I: Water drinking mice proximal colon, II: DSS treated mice
proximal colon, III: Water drinking mice distal colon, IV: DSS treated mice distal colon. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0006073.g007
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in the experiments. Colitis was induced by the addition of DSS
[40,000 Da, 3.5% (wt/vol), ICN Biochemicals, Aurora, OH] to
the drinking water. The mean DSS-water consumption was
recorded for each group. Groups of mice (n=6 mice/group) were
treated with 3.5% DSS or regular water for the indicated days.
Body weights were assessed every day during the treatment period.
Histological assessment of colitis was performed by H&E staining
and analyzed by microscopy. All animal experiments were
approved by The Animal Care Committee of Emory University,
Atlanta and were in accordance with the guide for the Care and
Use of Laboratory Animal, published by the U.S. Public Health
Service.
Clinical activity
Colitis was quantified with clinical activity, as described
previously [17] using the parameters of weight loss, stool
consistency, and fecal blood which were determined daily for
each mouse. Five days after the induction of colitis, mice were
euthanized by CO2/hypothermia. The abdominal cavity was
exposed by a midline laparotomy, and the entire colon was
removed from the caecum to the anus. The length of the colon was
measured, the colon was flushed with cold PBS and opened
longitudinally for morphologic studies, and tissue obtained from
each colon was processed for further assays.
Histological assessment of colitis
Specimens from proximal and distal parts of colon were stained
with hematoxylin, histological features were analyzed for these
microscopic sections as described previously [17], according to the
severity of the induced damage.
Myeloperoxidase (MPO) activity
Neutrophil infiltration into colon was quantified by measuring
MPO activity [35,36]. Briefly, a portion of colon was homogenized
in 1:20 (w/v) of 50 mM phosphate buffer (pH 6.0) containing
0.5% hexadecyltrimethyl ammonium bromide (Sigma-Aldrich,
ST. Louis, MO) on ice using a Polytron homogenizer. The
homogenate was sonicated for 10 s, Freeze-thawed three times,
and centrifuged at 14,000 rpm for 15 min. Supernatant (14 ml)
was added to 1 mg/ml o-dianisidine hydrochloride (Sigma-
Aldrich, ST. Louis, MO) and 0.0005% hydrogen peroxide, and
the change in absorbance at 460 nm was measured. One unit of
MPO activity was defined as the amount that degraded 1 mmol
peroxidase per minute at 25uC. The results were expressed as
absorbance per gram of tissue.
In vivo permeability assay
In vivo permeability assay to assess barrier function was
performed using an FITC-labeled dextran method, as described
[37]. Briefly, 8- to 10-wk-old mice were used. Food and water were
withdrawn for 4 h and mice were gavaged with permeability
tracer (60 mg/100 g body weight of FITC-labeled dextran, MW
4000; Sigma-Aldrich). Serum was collected retro-orbitally; fluo-
rescence intensity of each sample was measured (excitation,
492 nm; emission, 525 nm; Cytofluor 2300; Millipore, Waters
Chromatography); and FITC-dextran concentrations were deter-
mined from standard curves generated by serial dilution of FITC-
dextran. Permeability was calculated by linear regression of
sample fluorescence (Excel 5.0; Microsoft).
Real time PCR
Colons were removed from euthanized mice, washed to remove
fecal matter and then divided three of each group into sections
corresponding to proximal colon (caecum to mid-transverse colon)
and distal colon (mid-transverse colon to anus). Total RNA was
extracted using TRIzol (Invitrogen, Carlsbad, CA) from colon
mucosa from whole or parts of colon of DSS-treated mice and
then reverse transcribed using the Thermoscript
TM RT-PCR
System (Invitrogen, Carlsbad, CA) and purified with the RNeasy
Mini Kit (Qiagen, Germantown, MD). Real time PCR was
performed using iQ SYBR Green Supermix kit (BioRad, Hercules,
CA) with the iCycler sequence detection system (BioRad,
Hercules, CA). Specific primers were designed using the Primer
Express Program (Applied Biosystems, Foster City, CA): TNF-a,
IL-1, IL-6, KC, IFN-c, IL-10 IL-12 and MIP-2, 36B4 acts as
internal control (Table 1). For graphical representation of
quantitative PCR data, raw cycle threshold values (Ct values)
obtained for target samples were deducted from the Ct value
obtained for internal control transcript levels, using the DDCt
method as follows: DDCT=(Ct,target2Ct,con)treatment2(Ct,target2
Ct,con)non-treatment, and the final data were derived from 2
2DDCT.
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Table 1. Primers used for proinflammatory mediators
quantification.
Name Nucleotide sequence
34B4For 59 TCCAGGCTTTGGGCATCA 39
36B4 Rev 59 CTTTATCAGCTGCACATCACTCAGA-39
TNF-a For 59 AGGCTGCCCCGACTACGT 39
TNF-a Rev 59 GACTTTCTCCTGGTATGAGATAGCAAA 39
IFN-c For 59 CAGCAACAGCAAGGCGAAA39
IFN-c Rev 59 CTGGACCTGTGGGTTGTTGAC 39
IL-1b For 59 TCG CTCAGGGTCACAAGAAA 39
IL-1b Rev 59 CATCAGAGGCAAGGAGGAAAAC 39
IL-6 For 59 ACAAGTCGGAGGCTTAATTACACAT 39
IL-6 Rev 59 TTGCCATTGCACAACTCTTTTC 39
KC For 59 CTTGAAGGTGTTGCCCTCAG 39
KC Rev 59 TGGGGACACCTTTTAGCATC 39
IL-10 For 59 GGTTGCCAAGCCTTATCGGA 39
IL-10 Rev 59 ACCTGCTCCACTGCCTTGCT 39
IL-12 For 59 AGACCCTGCCCATTGAACTG 39
IL-12 Rev 59 GAAGCTGGTGCTGTAGTTCTCATATTT 39
MIP-2 For 59 GGCAAGGCTAACTGACCTGGAAAGG 39
MIP-2 Rev 59 ACAGCGAGGCACATCAGGTACGA 39
Note: TNF-a: Tumor necrosis factor-alpha, IFN-c: Interferon-gamma, IL-1b:
Interleukin-1 beta, IL-6: Interleukin-6, KC: Keratinocyte-derived Chemokine, MIP-
2: macrophage inflammatory protein-2, IL-10: Interleukin-10, IL-12: Interleukin-
12, For: Forward, Rev: Reverse.
doi:10.1371/journal.pone.0006073.t001
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